805 KING FARM BOULEVARD, SUITE 550
ROCKVILLE MD 20850
Business Phone: 3019613400
• ROCKVILLE, MD How do I update this listing?
Sucampo Pharmaceuticals is based out of Rockville. Sucampo Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones. It develops prostones for the treatment of gastrointestinal, respiratory, vascular, and central nervous system diseases and disorders. The company's principal product includes AMITIZA, which is used for the treatment of chronic idiopathic constipation in adults and is approved by FDA for use by adults primarily in the United States. Sucampo Pharmaceuticals is also conducting two pivotal Phase III clinical trials of AMITIZA for the treatment of irritable bowel syndrome with constipation. Its additional compounds in development include SPI-8811, used for the treatment of ulcers induced by nonsteroidal anti-inflammatory drugs (NSAID), portal hypertension, nonalcoholic fatty liver disease, cystic fibrosis, and chronic obstructive pulmonary disease; and SPI-017, used for the treatment of peripheral arterial and vascular disease, and central nervous system disorders. The company has completed Phase I trials of SPI-8811 for NSAID-induced ulcers; a Phase IIa trial for nonalcoholic fatty liver disease; and a Phase IIa trial for cystic fibrosis. It is also developing an oral formulation of SPI-017 for the treatment of Alzheimer's disease. In addition, the company plans to begin Phase II/III pivotal clinical trials of AMITIZA for the treatment of opioid-induced bowel dysfunction. Sucampo Pharmaceuticals has a collaboration and license agreement with Takeda Pharmaceutical Company Limited to jointly develop and commercialize AMITIZA for chronic idiopathic constipation, irritable bowel syndrome with constipation, opioid-induced bowel dysfunction, and other gastrointestinal indications in the United States and Canada. The company was founded by Sachiko Kuno and Ryuji Ueno in 1996.Whalewisdom has at least 232 Form 4 filings The firm has no submitted 13F filings and does not appear to be an investment advisor.